Qube Research & Technologies LTD Ascendis Pharma A/S Transaction History
Qube Research & Technologies LTD
- $65.7 Billion
- Q3 2024
A detailed history of Qube Research & Technologies LTD transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Qube Research & Technologies LTD holds 5,551 shares of ASND stock, worth $726,348. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,551
Previous 54,748
89.86%
Holding current value
$726,348
Previous $7.47 Million
88.91%
% of portfolio
0.0%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding ASND
# of Institutions
244Shares Held
58.8MCall Options Held
250KPut Options Held
377K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.27 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.13MShares$672 Million3.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$653 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.41MShares$577 Million1.03% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$548 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.3B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...